SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - FRA:1SXP - DE000A3ENQ51 - Common Stock
21.85 EUR
+0.2 (+0.92%)
We assign a fundamental rating of 5 out of 10 to 1SXP. 1SXP was compared to 20 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. 1SXP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
1SXP had a positive operating cash flow in the past year.
1SXP had positive earnings in each of the past 5 years.
Each year in the past 5 years 1SXP had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.61%, 1SXP belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
With an excellent Return On Equity value of 17.01%, 1SXP belongs to the best of the industry, outperforming 85.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 13.93%, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 7.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROIC | 13.93% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a Profit Margin of 15.05%. This is in the better half of the industry: 1SXP outperforms 80.00% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
1SXP's Operating Margin of 19.47% is fine compared to the rest of the industry. 1SXP outperforms 75.00% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 33.73%, 1SXP is in line with its industry, outperforming 45.00% of the companies in the same industry.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1SXP is creating value.
1SXP has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, 1SXP has a worse debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 1.74, which is an excellent value as it means it would take 1SXP, only 1.74 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.74, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
1SXP has a better Debt to Equity ratio (0.09) than 95.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | N/A |
ROIC/WACC1.7
WACC8.19%
2.3 Liquidity
A Current Ratio of 1.57 indicates that 1SXP should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.57, 1SXP is in line with its industry, outperforming 45.00% of the companies in the same industry.
A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
The Quick ratio of 1SXP (1.17) is worse than 65.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.00%.
1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.04% yearly.
Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 2.86% in the last year.
1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.84% yearly.
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
The Earnings Per Share is expected to grow by 10.56% on average over the next years. This is quite good.
1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.81% yearly.
EPS Next Y4.64%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.56%
Revenue Next Year3.22%
Revenue Next 2Y6.56%
Revenue Next 3Y8.07%
Revenue Next 5Y7.81%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 22.53, the valuation of 1SXP can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 65.00% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.38. 1SXP is around the same levels.
Based on the Price/Forward Earnings ratio of 18.05, the valuation of 1SXP can be described as rather expensive.
Based on the Price/Forward Earnings ratio, 1SXP is valued a bit cheaper than the industry average as 70.00% of the companies are valued more expensively.
1SXP is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.53 | ||
| Fwd PE | 18.05 |
4.2 Price Multiples
80.00% of the companies in the same industry are more expensive than 1SXP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than the industry average as 70.00% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 66.38 | ||
| EV/EBITDA | 12.41 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1SXP's earnings are expected to grow with 12.50% in the coming years.
PEG (NY)4.86
PEG (5Y)N/A
EPS Next 2Y10.58%
EPS Next 3Y12.5%
5. Dividend
5.1 Amount
1SXP has a yearly dividend return of 0.74%, which is pretty low.
The stock price of 1SXP dropped by -20.84% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
1SXP's Dividend Yield is a higher than the industry average which is at 0.73.
With a Dividend Yield of 0.74, 1SXP pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.74% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.41% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.41%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
FRA:1SXP (9/22/2025, 5:29:34 PM)
21.85
+0.2 (+0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.29B
Analysts76.84
Price Target29.89 (36.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.74% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.41%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.42%
PT rev (3m)-2.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)0.61%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-1.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.53 | ||
| Fwd PE | 18.05 | ||
| P/S | 3.37 | ||
| P/FCF | 66.38 | ||
| P/OCF | 16.17 | ||
| P/B | 3.81 | ||
| P/tB | 3.95 | ||
| EV/EBITDA | 12.41 |
EPS(TTM)0.97
EY4.44%
EPS(NY)1.21
Fwd EY5.54%
FCF(TTM)0.33
FCFY1.51%
OCF(TTM)1.35
OCFY6.19%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)4.86
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROCE | 17.04% | ||
| ROIC | 13.93% | ||
| ROICexc | 14.46% | ||
| ROICexgc | 14.87% | ||
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% | ||
| FCFM | 5.08% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexcg growth 3Y-8.59%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204.37% | ||
| Cap/Sales | 15.78% | ||
| Interest Coverage | 12.16 | ||
| Cash Conversion | 76.71% | ||
| Profit Quality | 33.75% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.19%
ROIC/WACC1.7
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y4.64%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.56%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year3.22%
Revenue Next 2Y6.56%
Revenue Next 3Y8.07%
Revenue Next 5Y7.81%
EBIT growth 1Y12.19%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year39.55%
EBIT Next 3Y25.42%
EBIT Next 5Y18.43%
FCF growth 1Y-28.77%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.41%
OCF growth 3Y19.45%
OCF growth 5YN/A